Figure 4. HRs for the Interaction of Treatment Exposure With Patient Baseline Characteristics in the Overall Cohort and Patient Subgroups.

GLA (glucose-lowering agent) includes acarbose, glucagon-like peptide-1 receptor agonists, insulin, meglitinides, metformin, sulfonylureas, and thiazolidinedione. aDCSI indicates adapted Diabetes Complications Severity Index; CVD, cardiovascular disease; DPP4is, dipeptidyl peptidase 4 inhibitors; eGFR, estimated glomerular filtration rate; HR, hazard ratio; and SGLT2is, sodium-glucose cotransporter 2 inhibitors.

^aEvents included the first and repeat CVD events.

^bHistory of any CVD was determined from inpatient, outpatient, and emergency department medical records.